Your session is about to expire
← Back to Search
Pimavanserin PET Tracer for Neurodegenerative Disease
Study Summary
This trialwill compare 5HT2A receptor density between neurodegenerative patients and healthy controls to see if there's a difference.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2021 Phase 4 trial • 6 Patients • NCT04188392Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I have been diagnosed with a neurodegenerative disease like Parkinson's or Huntington's.I am the same age and gender as the patient group.I have Parkinson's and have taken or am taking pimavanserin.I have not taken antipsychotic medications in the last 2 weeks.I have had severe hallucinations or delusions weekly for a month after being diagnosed with Parkinson's.I am unable to complete tests for brain function.I have not had a stroke or any serious uncontrolled illness.I am unable to give consent on my own.I haven't taken any serotonergic medications in the last 6 weeks.I have psychosis not caused by substance abuse or a primary mental health condition.
- Group 1: Pimavanserin
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Drug Has Already Been Approved - The FDA has already approved this drug, and is just seeking more data.
- Pivotal Trial - The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Are elderly individuals aged 45+ able to join this clinical investigation?
"This trial is only open to patients aged 50-85. However, there are 30 trials available for those under 18 and 502 that cater to individuals over 65 years of age."
Has Pimavanserin been granted clearance by the Food and Drug Administration?
"The safety profile of Pimavanserin is rated highly, as it has achieved Phase 4 approval and thus earned a score of 3."
Are there any vacancies left in this investigation for participants?
"Affirmative. Clinicaltrials.gov's data reveals that this research is still recruiting, having first been posted on the 23rd of January 2023 and last edited 24 hours later. The study requires 75 patients from a single site to complete it."
How many individuals have registered to participate in this trial?
"That is correct. According to clinicaltrials.gov, the medical investigation was first published on January 23rd of 2023 and has been actively searching for participants since then. The study requires 75 patients from a single research site."
Is eligibility open to me for this research endeavor?
"75 participants with Parkinson's disease between the ages of 50 and 85 are eligible to partake in this medical research. Those hoping to be included must meet further criteria, such as having a study partner available for visits, psychoses (including delusions or hallucinations) that require treatment occurring weekly over four weeks post-diagnosis, and healthy counterparts who match participant age and gender."
Share this study with friends
Copy Link
Messenger